Cystatin C levels in plasma and peripheral blood mononuclear cells among hyperhomocysteinaemic subjects: effect of treatment with B-vitamins

Kari Anne R. Tobin¹,², Kirsten B. Holven³, Kjetil Retterstøl¹, Ellen Strøm¹, Leiv Ose¹, Pål Aukrust²,⁴ and Marit S. Nenseter¹,²,⁴

¹Lipid Clinic, Oslo University Hospital, Rikshospitalet, 0027 Oslo, Norway
²Research Institute for Internal Medicine, Oslo University Hospital, Rikshospitalet, University of Oslo, 0027 Oslo, Norway
³Department of Nutrition, Institute for Basic Medical Sciences, University of Oslo, Oslo, Norway
⁴Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, University of Oslo, 0027 Oslo, Norway

(Received 25 March 2009 – Revised 17 June 2009 – Accepted 22 June 2009 – First published online 17 August 2009)

Homocysteine has been related to increased risk of CVD. Matrix degradation and inflammation may be involved in this link between hyperhomocysteinaemia and CVD. Recent studies suggest that cystatin C can modulate matrix degradation and inflammation. The present study measured cystatin C at protein (plasma) and mRNA levels (peripheral blood mononuclear cells (PBMC)) in hyperhomocysteinaemic individuals (n 37, female seven and male thirty, aged 20–70 years) before and after B-vitamin supplementation for 3 months in a randomised, placebo-controlled double-blind trial. In a cross-sectional study, seventeen of the hyperhomocysteinaemic subjects were age- and sex-matched to healthy controls (n 17). Our main findings were: (i) as compared with controls, hyperhomocysteinaemic subjects tended to have higher plasma concentrations of cystatin C and lower mRNA levels of cystatin C in PBMC; (ii) compared with placebo, treatment of hyperhomocysteinaemic individuals with B-vitamins significantly increased plasma levels of cystatin C and mRNA levels of cystatin C in PBMC; (iii) while plasma levels of cystatin C were positively correlated with plasma levels of TNF receptor-1, mRNA levels of cystatin C in PBMC were inversely correlated with this TNF parameter. Taken together, our findings suggest that disturbed cystatin C levels may be a characteristic of hyperhomocysteinaemic individuals, potentially related to low-grade systemic inflammation in hyperhomocysteinaemic subjects, and that B-vitamins may modulate cystatin C levels in these individuals.

Homocysteine: B-vitamins: Cystatin C: Inflammation: Atherosclerosis

Epidemiological studies have established that elevated plasma levels of homocysteine are associated with an increased risk of ischaemic stroke, myocardial infarction and venous thromboembolism(1–3). In addition, animal models of hyperhomocysteinaemia have shown abnormalities of vascular structure and function(4). Paradoxically, however, clinically controlled trials failed to show that lowering homocysteine with vitamin B therapy as secondary prevention reduced risk of CVD or mortality(5–7). In contrast, the recently reported improvement in stroke mortality observed after folic acid fortification in the United States and Canada, but not in England and Wales (where fortification is not mandatory), is consistent with the hypothesis that folic acid fortification helps to reduce deaths from stroke(8). These findings are supported by a recent meta-analysis, showing that folic acid supplementation can effectively reduce the risk of stroke in primary prevention(9). Thus, the homocysteine hypothesis in CVD is not dead(10), and the precise mechanism by which hyperhomocysteinaemia is related to atherogenesis needs to be further elucidated.

Inflammation and matrix degradation play important roles in the pathogenesis of atherosclerosis and plaque destabilisation. Previously, we have shown that hyperhomocysteinaemic subjects are characterised by raised serum levels of inflammatory cytokines and matrix metalloproteinases, potentially reflecting a pathogenic loop between inflammation and matrix degradation in the development of hyperhomocysteinaemia-related CVD(11–15).

The main determinants of elevated plasma concentration of homocysteine are deficiency of vitamins B₁₂, B₉ and folate, polymorphism in the methyl tetrahydrofolate reductase gene and impaired renal function. There is an inverse relationship between homocysteine and glomerular filtration rate throughout the whole range of renal function(14,15). Plasma concentration of cystatin C, a low molecular weight protein produced by all nuclear cells, has been considered to be a better marker of glomerular filtration rate than plasma creatinine(14,15). Interestingly, recent reports suggest a pivotal role for cystatin C in plaque stability potentially involving interaction with matrix degradation(16–18). Cystatin C is the most...
abundant endogenous inhibitor of cysteine proteases, in particular of cathepsins S and K. Local deficiency of cystatin C in human atherosclerotic and aneurysmal aortic lesions has been reported, suggesting an imbalance between cystatin C and the cathepsins that would favour matrix degradation\cite{17–19}. Moreover, data from knock-out mice models of cystatin C point to a role of cystatin C as an anti-atherogenic protein, protecting against enhanced elastin degradation\cite{18}.

In contrast to reports on low levels of cystatin C at the cellular levels within the atherosclerotic lesion, conflicting data are reported regarding the association of plasma levels of cystatin C and risk of CVD\cite{19–26}. However, few studies, if any, have compared plasma levels of cystatin C with its accompanying intracellular expression within the same individuals. We hypothesise a role for cystatin C in the pathogenesis of hyperhomocysteinaemia-related CVD, and in the present study we examined cystatin C levels in plasma and in peripheral blood mononuclear cells (PBMC) from the same hyperhomocysteinaemic individuals as well as in normohomocysteinaemic control subjects. We also examined the ability of B-vitamins to modulate these parameters in hyperhomocysteinaemia.

Subjects and methods

Subjects

Thirty-seven adults of 20–70 years of age with hyperhomocysteinaemia (fasting plasma total homocysteine concentration >15 µmol/l at screening) were recruited at the Lipid Clinic and the Department of Medical Biochemistry, Oslo University Hospital, Rikshospitalet and at Department of Clinical Chemistry, Oslo University Hospital, Ullevål, Oslo, Norway. In the cross-sectional study, seventeen of the hyperhomocysteinaemic subjects were sex and age matched to healthy control subjects (n 17), who were health care workers with no history of hypertension, diabetes, CVD or other acute or chronic illness, consecutively recruited in the same period and from the same area of Norway (eastern part). The study was conducted according to the Declaration of Helsinki, and all procedures involving the subjects were approved by the Regional Committee for Medical and Health Research Ethics, Asnieres, France.

Study design and inclusion/exclusion criteria have been published previously\cite{27}. Thirty-eight hyperhomocysteinaemic subjects completed the study\cite{27}. In the present study, serum and plasma samples were available from all but one participant in the TrioBe® group (n 37; n 18 and n 19 in the placebo and B-vitamin groups, respectively), and PBMC were available from twenty-nine participants (fourteen in the placebo group and fifteen in B-vitamin group). The hyperhomocysteinaemic subjects were randomised to receive either TrioBe® (cyanocobalamin 0·5 mg, pyridoxine hydrochloride 3·0 mg and folic acid 0·8 mg; 1 tablet/d; Recip AB, Arsta, Sweden) or an identical-appearing placebo tablet (1 tablet/d; Recip AB) for 3 months in a double-blind fashion. Reduced renal function according to plasma creatinine concentration was an exclusion criterion. Compliance as judged by pill count of returned, unused pills was 91 (sd 7) % and 87 (sd 6) % (P=0·11) in the TrioBe® and placebo group, respectively.

Blood sampling protocol

Venous blood samples were collected after an overnight fast and without medication ingestion in the morning of sampling. Plasma and serum were processed and stored at −80°C. All analyses, except the routine laboratory assays, were performed after the last patients had completed the treatment period. To avoid run-to-run variability, serial samples from a given subject were analysed at the same time.

Cell isolation

PBMC were obtained from heparinised blood by gradient centrifugation in Isopaque–Ficoll (Lymphoprep, Nycomed, Oslo, Norway). PBMC pellets for RNA analysis were immediately frozen and stored at −80°C.

Quantitative real-time RT-PCR

Total RNA was isolated from PBMC pellets as described previously\cite{29}. To detect gene expression of cystatin C, 0·1 µg total RNA from each sample was reverse transcribed by TaqMan high-capacity reverse transcription reagent kit (Applied Biosystems, Foster City, CA, USA). For quantitative real-time RT-PCR amplification, sequence specific PCR primers for cystatin C were designed using the Primer Express software version 1·5 (Applied Biosystems): forward primer: 5’-AGACCCAGCCCA-ACTTGGA-3’, reverse primer: 5’-AGCAGAATGCTTTCC-TTTCAGA-3’. The b-actin was used as a housekeeping gene for normalisation (Applied Biosystems).

Enzyme immunoassays

Plasma concentrations of cystatin C and TNF receptor (TNFR)-1 were quantified by enzyme immunoassays from R&D Systems (Minneapolis, MN, USA). According to the manufacturer, cystatin C concentration in EDTA plasma from thirty-six individuals ranged from 560 to 1173 ng/ml, mean 774 (sd 155) ng/ml.

Routine laboratory assays

Concentrations of homocysteine were measured on the Abbott IMx analyzer (Abbott Laboratories, Abbott Park, IL, USA); serum folate and serum vitamin B12 on the Wallac AutoDelfia analyzer (Wallac Oy, Turku, Finland); total cholesterol, LDL cholesterol, HDL cholesterol, TAG, creatinine and C-reactive protein were measured using the Modular-P platform (Roche Diagnostics, F. Hoffmann-La Roche Ltd, Basel, Switzerland); and fibrinogen by STA-R Evolution (Diagnostica Stago, Asnieres, France).

Statistical analysis

Data are given as means and standard deviations or median (minimum–maximum) if not otherwise stated. Data from patients and controls and differences in changes between
Results

Cystatin C in hyperhomocysteinaemic subjects and age- and sex-matched healthy control subjects – cross-sectional testing

Characteristics of the participants in the cross-sectional study are given in Table 1. The expected differences in homocysteine and folate levels were observed. Although controls showed significantly higher creatinine levels compared with homocysteinaemic subjects, all creatinine values were within the normal range (Table 1). While there was a tendency towards higher plasma concentration of cystatin C in hyperhomocysteinaemic patients as compared with controls (Table 1; Fig. 1(a); P=0·001), an opposite pattern was seen in PBMC with a tendency towards lower mRNA levels of cystatin C in cells from those with hyperhomocysteinaemia (Table 1; Fig. 1(b); P=0·060).

Effect of B-vitamin therapy on cystatin C levels in hyperhomocysteinaemia

Next, we conducted a randomised, placebo-controlled double-blind trial with B-vitamin therapy for 3 months in the hyperhomocysteinaemic subjects (n 37). There were no significant differences between the TrioBe® treatment group (n 19) and the placebo group (n 18) at baseline (Table 2). Whereas 3 months of TrioBe® treatment increased serum levels of folate from 7·5 (SD 2·9) nmol/l to 37·8 (SD 14·9) nmol/l, P<0·001, and of vitamin B₁₂ from 227 (SD 81) pmol/l to 425 (SD 177) pmol/l, P<0·001, the plasma concentration of homocysteine was reduced from 19 (13–65) μmol/l to 9 (6–20) μmol/l, n 19; P<0·001. In contrast, no significant differences in these parameters occurred within the placebo group (data not shown).

There were no significant differences in plasma concentrations of cystatin C between the two treatment groups at baseline (P=0·331; Table 2). While no significant changes in cystatin C were observed within the placebo group (P=0·528), TrioBe® treatment for 3 months significantly increased plasma concentration of cystatin C (840 (SD 253) v. 969 (SD 300) ng/ml, P=0·010) without any changes in creatinine levels (data not shown), resulting in a significant difference in changes between the two treatment groups (P=0·013; Fig. 2(a)).

At baseline, there were no significant differences in mRNA levels of cystatin C in PBMC between the two treatment groups (P=0·275; Table 2; n 14 and n 15 in the placebo and TrioBe® groups, respectively). While no significant changes occurred in the placebo group (P=0·433), TrioBe® treatment was accompanied by a significant increase in mRNA levels of cystatin C in PBMC (0·77 (SD 0·19) v. 0·84 (SD 0·20); P=0·041), resulting in a significant difference in changes between the two treatment groups (P=0·029; Fig. 2(b)).

Correlations between cystatin C and clinical and inflammatory parameters in hyperhomocysteinaemic subjects in the TrioBe® study – baseline data

Plasma concentrations of cystatin C were significantly correlated to creatinine levels (n 37, r 0·729; P<0·001) and BMI

<table>
<thead>
<tr>
<th>Table 1. Characteristics of participants in the cross-sectional study</th>
<th>(Mean, median, standard deviations and min–max values)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hyperhomocysteinaemic subjects (n 17)</strong></td>
<td><strong>Control subjects (n 17)</strong></td>
</tr>
<tr>
<td><strong>Mean</strong></td>
<td><strong>Median</strong></td>
</tr>
<tr>
<td>Age (years)</td>
<td>45·2</td>
</tr>
<tr>
<td>Male (n)</td>
<td>13</td>
</tr>
<tr>
<td>CVD (n)</td>
<td>4*</td>
</tr>
<tr>
<td>Statin treatment (n)</td>
<td>7*</td>
</tr>
<tr>
<td>Current smokers (n)</td>
<td>8*</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24·0</td>
</tr>
<tr>
<td>Homocysteine (μmol/l)</td>
<td>8·7†</td>
</tr>
<tr>
<td>Folate (nmol/l)</td>
<td>250</td>
</tr>
<tr>
<td>Vitamin B₁₂ (pmol/l)</td>
<td>4·9</td>
</tr>
<tr>
<td>TAG (mmol/l)</td>
<td>3·1</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/l)</td>
<td>1·4</td>
</tr>
<tr>
<td>Creatinine (μmol/l)</td>
<td>1·0</td>
</tr>
<tr>
<td>C-reactive protein (mg/l)</td>
<td>77†</td>
</tr>
<tr>
<td>Cystatin C (ng/ml)</td>
<td>1054†</td>
</tr>
<tr>
<td>mRNA cystatin C:β-actin</td>
<td>0·77§</td>
</tr>
</tbody>
</table>

min. Minimum; max. maximum.

n indicates number of individuals.

For mRNA data, n 14 in both groups.

P<0·05 v. control subjects.

P<0·01 v. control subjects.

P=0·065 v. control subjects.

P=0·060 v. control subjects.
a significant inverse correlation between gene expression of cystatin C and plasma levels of TNFR-1 (r = 0.441; P=0.027). There was no correlation between the levels of cystatin C in plasma and PBMC (n 29; P=0.968).

**Discussion**

Recent reports suggest a pivotal role for cystatin C in atherosclerotic plaque destabilisation (16–19). However, whereas low levels of cystatin C were found in atherosclerotic plaques in both human subjects and mice, conflicting data are reported on plasma concentrations of cystatin C, and the relationship between circulating and intracellular cystatin C levels is not fully understood. In the present study, we show that: (i) as compared with age- and sex-matched healthy controls, the hyperhomocysteinaemic subjects tended to have higher concentrations of cystatin C in plasma and lower mRNA levels of cystatin C in PBMC; (ii) compared with placebo, treatment of hyperhomocysteinaemic individuals with vitamins B12, B6 and folic acid (TrioBe®) for 3 months significantly increased plasma levels of cystatin C as well as gene expression levels of cystatin C in PBMC; (iii) while plasma levels of cystatin C were positively correlated with plasma levels of TNFR-1, mRNA levels of cystatin C in PMBC were inversely correlated with this marker of activity in the TNF system. Taken together, these findings may suggest a dysregulated cystatin C metabolism in hyperhomocysteinaemic individuals, characterised by elevated plasma levels of cystatin C and low levels of cystatin C mRNA in PBMC. In both compartments, cystatin C levels seem to be related to increased activity in the TNF system with a positive correlation to plasma and a negative correlation to intracellular cystatin C levels. Moreover, our findings also suggest a role for B-vitamins in the modulation of cystatin C levels in hyperhomocysteinaemic individuals.

Whereas normal arteries express abundant cystatin C, human atherosclerotic lesions have relatively low levels of cystatin C (19). Thus, data from knock-out mice models of cystatin C point to a role of cystatin C as an anti-atherogenic protein, protecting against enhanced elastin degradation (18). In contrast, most epidemiological studies support a relationship between high circulating levels of cystatin C and CVD (21–26). In the present study, we found that the hyperhomocysteinaemic patients tended to have lower mRNA levels of cystatin C in PBMC and higher plasma levels of cystatin C as compared with matched healthy control subjects. This pattern may suggest different origin of cystatin C levels in plasma and in mononuclear leukocytes. Since cystatin C is synthesised by all nucleated cells, plasma levels of cystatin C may be determined by global cystatin C production as well as by renal elimination (19,26). The relationship between the diminished expression of cystatin C found in atherosclerotic plaques and the elevated plasma levels of cystatin C in relation to CVD remains somewhat unclear. Furthermore, whether there is a direct atherogenic effect of systemically elevated cystatin C remains unknown (26). However, it is tempting to hypothesise that while the relationship between high plasma cystatin C levels and CVD reflects its property as a sensitive marker of impaired kidney function, decreased intracellular level of cystatin C in cells with relation to atherosclerosis (e.g. PBMC) could more directly contribute to
Cystatin C in hyperhomocysteinaemia

Table 2. Baseline characteristics of hyperhomocysteinaemic subjects in the vitamin B study
(Mean, median, standard deviations and min–max values)

<table>
<thead>
<tr>
<th></th>
<th>Placebo group (n 18)</th>
<th></th>
<th>TrioBe® group (n 19)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>Median</td>
<td>sd</td>
<td>Min–max</td>
</tr>
<tr>
<td>Age (years)</td>
<td>42.1</td>
<td>13.8</td>
<td>5</td>
<td>49.4</td>
</tr>
<tr>
<td>Male (n)</td>
<td>15</td>
<td></td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>CVD (n)</td>
<td>3</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Statin treatment (n)</td>
<td>6</td>
<td></td>
<td></td>
<td>9</td>
</tr>
<tr>
<td>Current smokers (n)</td>
<td>7</td>
<td></td>
<td></td>
<td>12</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.9</td>
<td>3.3</td>
<td>12.4</td>
<td>27.4</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>137</td>
<td>27</td>
<td>134</td>
<td>26</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>84</td>
<td>13</td>
<td>82</td>
<td>13</td>
</tr>
<tr>
<td>Homocysteine (µmol/l)</td>
<td>21</td>
<td></td>
<td>12–69</td>
<td></td>
</tr>
<tr>
<td>Folate (nmol/l)</td>
<td>9.2</td>
<td>3.5</td>
<td>0.07</td>
<td>7.5</td>
</tr>
<tr>
<td>Erythrocytes folate (nmol/l)</td>
<td>515</td>
<td>192</td>
<td>451</td>
<td>264</td>
</tr>
<tr>
<td>Vitamin B₁₂ (µmol/l)</td>
<td>242</td>
<td>85</td>
<td>227</td>
<td>81</td>
</tr>
<tr>
<td>Methylenalonic acid (µmol/l)</td>
<td>0.15</td>
<td>0.07</td>
<td>0.19</td>
<td>0.10</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>4.9</td>
<td>1.1</td>
<td>4.9</td>
<td>1.5</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/l)</td>
<td>3.1</td>
<td>0.9</td>
<td>3.2</td>
<td>1.4</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/l)</td>
<td>1.3</td>
<td>0.3</td>
<td>1.3</td>
<td>0.4</td>
</tr>
<tr>
<td>TAG (mmol/l)</td>
<td>1.2</td>
<td>0.4–3.5</td>
<td>1.1</td>
<td>0.3–5.1</td>
</tr>
<tr>
<td>Apo A-I (g/l)</td>
<td>1.5</td>
<td>0.2</td>
<td>1.4</td>
<td>0.3</td>
</tr>
<tr>
<td>Apo B (g/l)</td>
<td>0.9</td>
<td>0.2</td>
<td>0.9</td>
<td>0.3</td>
</tr>
<tr>
<td>Creatinine (µmol/l)</td>
<td>79</td>
<td>19</td>
<td>80</td>
<td>12</td>
</tr>
<tr>
<td>C-reactive protein (mg/l)</td>
<td>1.2</td>
<td>0.2–7.8</td>
<td>2.5</td>
<td>0.2–7.3</td>
</tr>
<tr>
<td>Fibrinogen (g/l)</td>
<td>3.2</td>
<td>0.6</td>
<td>3.5</td>
<td>0.9</td>
</tr>
<tr>
<td>TNF receptor-1 (pg/ml)</td>
<td>1133</td>
<td>328</td>
<td>1436</td>
<td>667</td>
</tr>
<tr>
<td>Cystatin C (ng/ml)</td>
<td>834</td>
<td>296</td>
<td>840</td>
<td>253</td>
</tr>
<tr>
<td>mRNA cystatin C:β-actin</td>
<td>0.83</td>
<td>0.19</td>
<td>0.77</td>
<td>0.19</td>
</tr>
</tbody>
</table>

min, Minimum; max, maximum.

n indicates number of individuals.

For mRNA data, n 14 and n 15 in the placebo and TrioBe® groups, respectively.

Cystatin C in hyperhomocysteinaemia

Atherogenesis through impaired inhibition of matrix degradation. Our findings that plasma levels but not cellular mRNA levels are positively correlated to creatinine may be in line with this notion. Furthermore, consistent with this hypothesis, leukocyte-specific expression of cystatin C in apoE-knock-out mice was actively involved in matrix remodelling associated with plaque regression (29). Thus, although further studies are needed, it is not inconceivable that the decreased expression of cystatin C in PBMC from hyperhomocysteinaemic subjects, at least partly, could contribute to the increased risk of CVD in these individuals. Moreover, the ability of TrioBe® to increase cystatin C mRNA levels in PBMC may suggest a beneficial effect of B-vitamins in hyperhomocysteinaemia. It is well documented that B-vitamin therapy to lower plasma homocysteine significantly reduces cardiovascular risk in patients with homocystinuria.

Inflammation is suggested to be a pathophysiological link between cystatin C and CVD (26). Thus, inflammatory cytokines such as TNFs have been found to reduce cystatin C expression in vascular endothelial cells (16). Furthermore, associations between plasma markers of inflammation and plasma levels of cystatin C were observed among subjects with and without coronary artery disease (31–33). The present study has the limitation that relatively few patients were included, and the role of cystatin C in the hyperhomocysteinaemia-related CVD should be further investigated in larger study populations. Such studies should also try to...
relate cystatin C levels to clinical manifestations of CVD in these individuals. Strengths of the present study, however, were that plasma levels and mRNA levels of cystatin C in PBMC were measured in the same individuals, the effect of homocysteine-lowering therapy was evaluated in subjects with hyperhomocysteinemia, and that impaired renal function as judged by creatinine was an exclusion criterion.

Our findings suggest that disturbed cystatin C levels may be a characteristic of hyperhomocysteinemic individuals, potentially related to low-grade systemic inflammation in these individuals. Further studies are needed to examine whether cystatin C could contribute to the increased risk of CVD that are observed in hyperhomocysteinemia. Our findings also suggest a role for B-vitamins in the modulation of cystatin C levels in hyperhomocysteinemic subjects.

Acknowledgements

We thank Liv Astrid Prestøy and Vígdis Bjerkely for their excellent technical assistance. This work was supported by grants from the Norwegian Foundation for Health and Rehabilitation and the Norwegian Association of Heart and Lung Patients. In addition, M. S. N. and K. B. H. received grant support (research funding) from Nycomed Pharma, and Recip AB. The other authors report no conflicts of interest. The contribution of each author was as follows: K. B. H., K. R., L. O., P. A. and M. S. N. planned and designed the study; K. R., L. O. and E. S. were responsible for the patients; E. S. was responsible for giving dietary advise and collecting information on dietary intake; K. A. R. T. and K. B. H. performed the experimental work; M. S. N. was responsible for the statistical analysis; K. B. H., P. A. and M. S. N. prepared the manuscript with comments taken from all authors.

References


